Clinical Trial Update: Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing EG12014 to Herceptin in HER2-positive early breast cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• EG12014 (EG12014)
• HERCEPTIN (trastuzumab)

Snippet

Sponsor: EirGenix, Inc. | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED